4DMEDICAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.62 AUD | +0.81% |
|
+11.71% | -13.29% |
| 10/05 | Transcript : 4DMedical Limited - Special Call | |
| 09/05 | 4DMedical's CT-Based Ventilation Product Secures US Medical Reimbursement for Scans; Shares Rise 5% | MT |
Valuation
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 360.8 | 173.8 | 231.2 | 240.7 | - | - |
| Enterprise Value (EV) 1 | 360.8 | 122.6 | 161.7 | 205.9 | 224.3 | 229.7 |
| P/E ratio | -15.3 x | -7.38 x | -6.7 x | -8.08 x | -10.5 x | -41 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1,663 x | 165 x | 322 x | 45.2 x | 12 x | 4.78 x |
| EV / Revenue | 1,663 x | 116 x | 225 x | 38.7 x | 11.2 x | 4.56 x |
| EV / EBITDA | - | -5.34 x | -5.6 x | -7.68 x | -12.7 x | -85.1 x |
| EV / FCF | -23.9 x | -4.39 x | -6.91 x | -5.01 x | -8.81 x | -30.6 x |
| FCF Yield | -4.18% | -22.8% | -14.5% | -19.9% | -11.4% | -3.27% |
| Price to Book | 4.16 x | 2.92 x | 3.24 x | 3.31 x | 4.36 x | 8.45 x |
| Nbr of stocks (in thousands) | 2,94,492 | 2,94,492 | 3,45,133 | 3,91,385 | - | - |
| Reference price 2 | 1.225 | 0.5900 | 0.6700 | 0.6150 | 0.6150 | 0.6150 |
| Announcement Date | 23/08/21 | 19/08/22 | 29/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.232 | 0.217 | 1.054 | 0.7186 | 5.327 | 20.08 | 50.37 |
| EBITDA 1 | - | - | -22.97 | -28.88 | -26.82 | -17.64 | -2.7 |
| EBIT 1 | -14.01 | -18.75 | -24.46 | -31.45 | -31.33 | -25.67 | -6.127 |
| Operating Margin | -1,136.9% | -8,640.44% | -2,320.28% | -4,376.71% | -588.23% | -127.8% | -12.16% |
| Earnings before Tax (EBT) 1 | -21.97 | -21.41 | -24.55 | -31.14 | -29.65 | -24 | -5.067 |
| Net income 1 | -21.98 | -21.42 | -24.59 | -31.46 | -29.91 | -23.45 | -4.9 |
| Net margin | -1,782.99% | -9,872.12% | -2,332.63% | -4,378.05% | -561.45% | -116.76% | -9.73% |
| EPS 2 | -0.1500 | -0.0800 | -0.0800 | -0.1000 | -0.0762 | -0.0587 | -0.0150 |
| Free Cash Flow 1 | -8.625 | -15.1 | -27.92 | -23.38 | -41.07 | -25.47 | -7.5 |
| FCF margin | -699.8% | -6,957.49% | -2,647.86% | -3,254.2% | -770.96% | -126.81% | -14.89% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 28/08/20 | 23/08/21 | 19/08/22 | 29/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: June | 2020 S2 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.0662 | - | - | - | 0.2327 | 0.7925 | 5.6 |
| EBITDA | - | - | - | - | - | - | -14.95 | - |
| EBIT 1 | -9.416 | -8.241 | -12.47 | - | - | -15.24 | -16.47 | -17.7 |
| Operating Margin | - | -12,439.43% | - | - | - | -6,550.47% | -2,077.69% | -316.07% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income 1 | -16.61 | -8.276 | -12.45 | -12.14 | -16.23 | -15.23 | -15.61 | -16.5 |
| Net margin | - | -12,492.14% | - | - | - | -6,543.97% | -1,969.24% | -294.64% |
| EPS | - | - | - | - | -0.0600 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 28/08/20 | 23/08/21 | 27/02/22 | 19/08/22 | 27/02/23 | 29/08/23 | 27/02/24 | - |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 51.1 | 69.6 | 34.8 | 16.4 | 11 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -8.63 | -15.1 | -27.9 | -23.4 | -41.1 | -25.5 | -7.5 |
| ROE (net income / shareholders' equity) | - | -25.7% | -34.4% | -48% | -38.6% | -41.1% | -8.3% |
| ROA (Net income/ Total Assets) | - | - | -29.5% | -37.6% | -27.9% | -20.2% | -2.8% |
| Assets 1 | - | - | 83.47 | 83.62 | 107.3 | 116.4 | 174.8 |
| Book Value Per Share 2 | -0.0800 | 0.2900 | 0.2000 | 0.2100 | 0.1900 | 0.1400 | 0.0700 |
| Cash Flow per Share 2 | - | -0.0500 | - | - | -0.0600 | -0.0500 | -0 |
| Capex 1 | - | - | 2.65 | 0.42 | 1.16 | 1.82 | 2.15 |
| Capex / Sales | - | - | 251.08% | 58.63% | 21.78% | 9.04% | 4.27% |
| Announcement Date | 28/08/20 | 23/08/21 | 19/08/22 | 29/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.615
AUD
Average target price
1.133
AUD
Spread / Average Target
+84.28%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.29% | 17Cr | |
| +12.06% | 23TCr | |
| +12.07% | 19TCr | |
| +13.88% | 14TCr | |
| +27.12% | 11TCr | |
| +0.91% | 6.36TCr | |
| +6.74% | 5.13TCr | |
| +13.39% | 5.1TCr | |
| +8.81% | 4.33TCr | |
| +4.14% | 3.7TCr |
- Stock Market
- Equities
- 4DX Stock
- Financials 4DMedical Limited